MMR alleges that drug store giant Walgreens infringes on health records patent Print
By Adam Meadows, Contributor   
Wednesday, 30 January 2013 05:38
icon_newsscoopA week ago, in an article titled  “Is MMRGlobal’s Personal Health Records Patent Portfolio Worth a Closer Look?”, we reported news about a published Valuation and Research report  by The Michael Bass Group, an investment banking and strategic advisory services firm focused on healthcare information technology, healthcare IT services, healthcare mobility providers, medical technology and devices.
That group had just released a patent valuation report for MMR Global (OTCQB : MMRF).

According to that report, there are more than 5500 hospitals, 150 PHR vendors and 750 EMR vendors as well as providers, payers and pharmacies that are potential licensees of the MMR Patent Portfolio. The report included MMR’s Global Patent Portfolio although the valuations were based on its U.S. portfolio.  Also, since the publication of that article the Company has announced that it is adding  Japan to the list of countries where it holds Health Information Technology patents. 
Sources now tell us that, MyMedicalRecords, Inc. has just filed a complaint for patent infringement against Walgreen Company (NYSE:WAG),  in the United States District Court for the Central District of California. 
The complaint, case number CV 13-00631, should be available on the court’s website starting Wednesday. 

As detailed in the complaint, MMR alleges that Walgreens infringes on MMR’s personal health records patent, specifically its US Patent No. 8,301,466.  The complaint seeks damages as well as a permanent injunction.
In an earlier press release, MMR announced that it has been investigating potential infringements by various groups  including, but not limited to, retail pharmacies and laboratory systems as well as hospitals, physicians and other healthcare professionals, using email, facsimile, file upload and voice. It appears that MMR is making good on its statements that it will protect its patent portfolio and any other IP it holds.

A person familiar with the complaint indicates that we can expect further developments regarding this matter in the days ahead.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus